Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.

Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsirigos A, Bronte V, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohashi PS, Brooks DG, McGaha TL.

Sci Immunol. 2019 Dec 13;4(42). pii: eaax8189. doi: 10.1126/sciimmunol.aax8189.

PMID:
31836669
2.

Evaluation of methods to assign cell type labels to cell clusters from single-cell RNA-sequencing data.

Diaz-Mejia JJ, Meng EC, Pico AR, MacParland SA, Ketela T, Pugh TJ, Bader GD, Morris JH.

Version 3. F1000Res. 2019 Mar 15 [revised 2019 Jan 1];8. pii: ISCB Comm J-296. doi: 10.12688/f1000research.18490.3. eCollection 2019.

3.

Translational genomics of nasopharyngeal cancer.

Tsang CM, Lui VWY, Bruce JP, Pugh TJ, Lo KW.

Semin Cancer Biol. 2019 Sep 12. pii: S1044-579X(19)30284-6. doi: 10.1016/j.semcancer.2019.09.006. [Epub ahead of print] Review.

4.

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.

Veitch ZW, Cescon DW, Denny T, Yonemoto LM, Fletcher G, Brokx R, Sampson P, Li SW, Pugh TJ, Bruce J, Bray MR, Slamon DJ, Mak TW, Wainberg ZA, Bedard PL.

Br J Cancer. 2019 Aug;121(4):318-324. doi: 10.1038/s41416-019-0517-3. Epub 2019 Jul 15.

PMID:
31303643
5.

Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours.

Jones DTW, Banito A, Grünewald TGP, Haber M, Jäger N, Kool M, Milde T, Molenaar JJ, Nabbi A, Pugh TJ, Schleiermacher G, Smith MA, Westermann F, Pfister SM.

Nat Rev Cancer. 2019 Aug;19(8):420-438. doi: 10.1038/s41568-019-0169-x. Epub 2019 Jul 12. Review.

PMID:
31300807
6.

High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma.

Johnston MJ, Nikolic A, Ninkovic N, Guilhamon P, Cavalli FMG, Seaman S, Zemp FJ, Lee J, Abdelkareem A, Ellestad K, Murison A, Kushida MM, Coutinho FJ, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Dirks PB, Pugh TJ, Morrissy S, St Croix B, Mahoney DJ, Lupien M, Gallo M.

Genome Res. 2019 Aug;29(8):1211-1222. doi: 10.1101/gr.246520.118. Epub 2019 Jun 27.

7.

High efficiency error suppression for accurate detection of low-frequency variants.

Wang TT, Abelson S, Zou J, Li T, Zhao Z, Dick JE, Shlush LI, Pugh TJ, Bratman SV.

Nucleic Acids Res. 2019 Sep 5;47(15):e87. doi: 10.1093/nar/gkz474.

8.

The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer.

Gupta A, Pugh TJ, Lam E, Sheridan AD, Nath S.

Oncology (Williston Park). 2019 May 14;33(5):187-91. No abstract available.

9.

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer.

Mason BR, Eastham JA, Davis BJ, Mynderse LA, Pugh TJ, Lee RJ, Ippolito JE.

J Natl Compr Canc Netw. 2019 May 1;17(5):506-513. doi: 10.6004/jnccn.2019.7306.

PMID:
31085758
10.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
11.

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U.

J Clin Invest. 2019 Apr 1;129(4):1801. doi: 10.1172/JCI128527. Epub 2019 Apr 1. No abstract available.

12.

Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma.

Hoffman M, Gillmor AH, Kunz DJ, Johnston MJ, Nikolic A, Narta K, Zarrei M, King J, Ellestad K, Dang NH, Cavalli FMG, Kushida MM, Coutinho FJ, Zhu Y, Luu B, Ma Y, Mungall AJ, Moore R, Marra MA, Taylor MD, Pugh TJ, Dirks PB, Strother D, Lafay-Cousin L, Resnick AC, Scherer S, Senger DL, Simons BD, Chan JA, Morrissy AS, Gallo M.

Cancer Res. 2019 May 1;79(9):2111-2123. doi: 10.1158/0008-5472.CAN-18-3441. Epub 2019 Mar 15.

PMID:
30877103
13.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

14.

CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling.

Mulder DT, Mahé ER, Dowar M, Hanna Y, Li T, Nguyen LT, Butler MO, Hirano N, Delabie J, Ohashi PS, Pugh TJ.

Blood Adv. 2018 Dec 11;2(23):3506-3514. doi: 10.1182/bloodadvances.2017014639. Erratum in: Blood Adv. 2019 Jan 22;3(2):121.

15.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

16.

Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders.

Pugh TJ, Fink JM, Lu X, Mathew S, Murata-Collins J, Willem P, Fang M; Cancer Genomics Consortium Plasma Cell Disorders Working Group.

Cancer Genet. 2018 Dec;228-229:184-196. doi: 10.1016/j.cancergen.2018.07.002. Epub 2018 Oct 5. Review.

PMID:
30393007
17.

Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.

Yang SYC, Lheureux S, Karakasis K, Burnier JV, Bruce JP, Clouthier DL, Danesh A, Quevedo R, Dowar M, Hanna Y, Li T, Lu L, Xu W, Clarke BA, Ohashi PS, Shaw PA, Pugh TJ, Oza AM.

Genome Med. 2018 Oct 31;10(1):81. doi: 10.1186/s13073-018-0590-x.

18.

Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma.

Karamboulas C, Bruce JP, Hope AJ, Meens J, Huang SH, Erdmann N, Hyatt E, Pereira K, Goldstein DP, Weinreb I, Su J, O'Sullivan B, Tiedemann R, Liu FF, Pugh TJ, Bratman SV, Xu W, Ailles L.

Cell Rep. 2018 Oct 30;25(5):1318-1331.e4. doi: 10.1016/j.celrep.2018.10.004.

19.

DNA hypermethylation within TERT promoter upregulates TERT expression in cancer.

Lee DD, Leão R, Komosa M, Gallo M, Zhang CH, Lipman T, Remke M, Heidari A, Nunes NM, Apolónio JD, Price AJ, De Mello RA, Dias JS, Huntsman D, Hermanns T, Wild PJ, Vanner R, Zadeh G, Karamchandani J, Das S, Taylor MD, Hawkins CE, Wasserman JD, Figueiredo A, Hamilton RJ, Minden MD, Wani K, Diplas B, Yan H, Aldape K, Akbari MR, Danesh A, Pugh TJ, Dirks PB, Castelo-Branco P, Tabori U.

J Clin Invest. 2019 Jan 2;129(1):223-229. doi: 10.1172/JCI121303. Epub 2018 Dec 3. Erratum in: J Clin Invest. 2019 Apr 1;129(4):1801.

20.

Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.

Hoffman KE, Voong KR, Levy LB, Allen PK, Choi S, Schlembach PJ, Lee AK, McGuire SE, Nguyen Q, Pugh TJ, Frank SJ, Kudchadker RJ, Du W, Kuban DA.

J Clin Oncol. 2018 Oct 10;36(29):2943-2949. doi: 10.1200/JCO.2018.77.9868. Epub 2018 Aug 14.

21.

Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification.

Robin TP, Maroni PD, Chin BB, La Rosa FG, Bernard B, Pugh TJ.

Oncology (Williston Park). 2018 Jul 15;32(7):360-3, 369, CV3. No abstract available.

22.

Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma.

Toker A, Nguyen LT, Stone SC, Yang SYC, Katz SR, Shaw PA, Clarke BA, Ghazarian D, Al-Habeeb A, Easson A, Leong WL, McCready DR, Reedijk M, Guidos CJ, Pugh TJ, Bernardini MQ, Ohashi PS.

Clin Cancer Res. 2018 Nov 15;24(22):5685-5696. doi: 10.1158/1078-0432.CCR-18-0554. Epub 2018 Jul 31.

23.

Prediction of acute myeloid leukaemia risk in healthy individuals.

Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, Barda N, Zuzarte PC, Heisler L, Sundaravadanam Y, Luben R, Hayat S, Wang TT, Zhao Z, Cirlan I, Pugh TJ, Soave D, Ng K, Latimer C, Hardy C, Raine K, Jones D, Hoult D, Britten A, McPherson JD, Johansson M, Mbabaali F, Eagles J, Miller JK, Pasternack D, Timms L, Krzyzanowski P, Awadalla P, Costa R, Segal E, Bratman SV, Beer P, Behjati S, Martincorena I, Wang JCY, Bowles KM, Quirós JR, Karakatsani A, La Vecchia C, Trichopoulou A, Salamanca-Fernández E, Huerta JM, Barricarte A, Travis RC, Tumino R, Masala G, Boeing H, Panico S, Kaaks R, Krämer A, Sieri S, Riboli E, Vineis P, Foll M, McKay J, Polidoro S, Sala N, Khaw KT, Vermeulen R, Campbell PJ, Papaemmanuil E, Minden MD, Tanay A, Balicer RD, Wareham NJ, Gerstung M, Dick JE, Brennan P, Vassiliou GS, Shlush LI.

Nature. 2018 Jul;559(7714):400-404. doi: 10.1038/s41586-018-0317-6. Epub 2018 Jul 9.

24.

Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple Myeloma.

Pugh TJ.

Semin Hematol. 2018 Jan;55(1):38-40. doi: 10.1053/j.seminhematol.2018.03.002. Epub 2018 Mar 7. Review.

25.

Who benefits most from early salvage radiation therapy after prostatectomy?

Nath SK, Rose BS, Pugh TJ.

Transl Androl Urol. 2018 Mar;7(Suppl 1):S124-S127. doi: 10.21037/tau.2017.11.23. No abstract available.

26.

Bamgineer: Introduction of simulated allele-specific copy number variants into exome and targeted sequence data sets.

Samadian S, Bruce JP, Pugh TJ.

PLoS Comput Biol. 2018 Mar 28;14(3):e1006080. doi: 10.1371/journal.pcbi.1006080. eCollection 2018 Mar.

27.

Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study.

Blanchard P, Pugh TJ, Swanson DA, Mahmood U, Chen HC, Wang X, Graber WJ, Kudchadker RJ, Bruno T, Feeley T, Frank SJ.

Brachytherapy. 2018 Mar - Apr;17(2):265-276. doi: 10.1016/j.brachy.2017.11.007. Epub 2017 Dec 18.

PMID:
29269207
28.

Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life Outcomes.

Frank SJ, Pugh TJ, Blanchard P, Mahmood U, Graber WJ, Kudchadker RJ, Davis JW, Kim J, Choi H, Troncoso P, Kuban DA, Choi S, McGuire S, Hoffman KE, Chen HC, Wang X, Swanson DA.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):374-382. doi: 10.1016/j.ijrobp.2017.09.050. Epub 2017 Oct 12.

29.

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial.

Voong KR, Lal LS, Kuban DA, Pugh TJ, Swint JM, Godby J, Choi S, Lee AK, Schlembach PJ, Frank SJ, McGuire SE, Hoffman KE.

Adv Radiat Oncol. 2017 Aug 1;2(3):249-258. doi: 10.1016/j.adro.2017.07.010. eCollection 2017 Jul-Sep.

30.

Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort.

Blanchard P, Davis JW, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, Achim M, McGuire SE, Matin SF, Nguyen Q, Mahmood U, Graber WJ, Chen HC, Wang X, Kuban DA.

BJU Int. 2018 Apr;121(4):540-548. doi: 10.1111/bju.14021. Epub 2017 Oct 17.

31.

Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy.

Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ, Guilhamon P, Lee L, Kushida MM, Pellacani D, Park NI, Coutinho FJ, Whetstone H, Selvadurai HJ, Che C, Luu B, Carles A, Moksa M, Rastegar N, Head R, Dolma S, Prinos P, Cusimano MD, Das S, Bernstein M, Arrowsmith CH, Mungall AJ, Moore RA, Ma Y, Gallo M, Lupien M, Pugh TJ, Taylor MD, Hirst M, Eaves CJ, Simons BD, Dirks PB.

Nature. 2017 Sep 14;549(7671):227-232. doi: 10.1038/nature23666. Epub 2017 Aug 30.

32.

Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas.

Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K, Mansouri S, Karimi S, Sahm F, von Deimling A, Taylor MD, Laperriere NJ, Pugh TJ, Aldape KD, Zadeh G.

Nat Commun. 2017 Aug 4;8(1):186. doi: 10.1038/s41467-017-00174-7.

33.

Implementation of hypofractionated prostate radiation therapy in the United States: A National Cancer Database analysis.

Stokes WA, Kavanagh BD, Raben D, Pugh TJ.

Pract Radiat Oncol. 2017 Jul - Aug;7(4):270-278. doi: 10.1016/j.prro.2017.03.011.

PMID:
28673554
34.

Recurrent and functional regulatory mutations in breast cancer.

Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, Baselga J, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G.

Nature. 2017 Jul 6;547(7661):55-60. doi: 10.1038/nature22992. Epub 2017 Jun 28.

35.

Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers.

Martin GV, Pugh TJ, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Blanchard P, Frank SJ.

Brachytherapy. 2017 Jul - Aug;16(4):761-769. doi: 10.1016/j.brachy.2017.04.004. Epub 2017 May 10.

36.

Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T, Li Z, Liu J, Mansour M, Masih-Khan E, Zhang T, Bratman SV, Oza AM, Kamel-Reid S, Trudel S, Pugh TJ.

Nat Commun. 2017 May 11;8:15086. doi: 10.1038/ncomms15086.

37.

Prostate brachytherapy, either alone or in combination with external beam radiation, is associated with longer overall survival in men with favorable pathologic Group 4 (Gleason score 8) prostate cancer.

Jackson MW, Amini A, Jones BL, Kavanagh B, Maroni P, Frank SJ, Mahmood U, Kudchadker RJ, Pugh TJ.

Brachytherapy. 2017 Jul - Aug;16(4):790-796. doi: 10.1016/j.brachy.2017.03.007. Epub 2017 Apr 23.

PMID:
28442277
38.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

39.

Data resources for the identification and interpretation of actionable mutations by clinicians.

Prawira A, Pugh TJ, Stockley TL, Siu LL.

Ann Oncol. 2017 May 1;28(5):946-957. doi: 10.1093/annonc/mdx023. Review.

PMID:
28327901
40.

Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging.

Martin GV, Pugh TJ, Mahmood U, Kudchadker RJ, Wang J, Bruno TL, Bathala T, Frank SJ.

Brachytherapy. 2017 Jul - Aug;16(4):728-733. doi: 10.1016/j.brachy.2017.02.001. Epub 2017 Mar 9.

41.

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, Oza AM.

J Clin Oncol. 2017 Apr 10;35(11):1240-1249. doi: 10.1200/JCO.2016.71.3677. Epub 2017 Feb 21.

PMID:
28221868
42.

Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database.

Amini A, Raben D, Crawford ED, Flaig TW, Kessler ER, Lam ET, Maroni P, Pugh TJ.

Urol Oncol. 2017 Jun;35(6):438-446. doi: 10.1016/j.urolonc.2017.01.013. Epub 2017 Feb 15.

PMID:
28214281
43.

A distinct innate lymphoid cell population regulates tumor-associated T cells.

Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, Milea A, Sowamber R, Katz SR, Bernardini MQ, Clarke BA, Shaw PA, Lang PA, Berman HK, Pugh TJ, Lanier LL, Ohashi PS.

Nat Med. 2017 Mar;23(3):368-375. doi: 10.1038/nm.4278. Epub 2017 Feb 6.

44.

Magnetic resonance imaging in prostate brachytherapy: Evidence, clinical end points to data, and direction forward.

Pugh TJ, Pokharel SS.

Brachytherapy. 2017 Jul - Aug;16(4):659-664. doi: 10.1016/j.brachy.2016.12.001. Epub 2017 Feb 1.

PMID:
28161432
45.

Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra.

Chmielecki J, Bailey M, He J, Elvin J, Vergilio JA, Ramkissoon S, Suh J, Frampton GM, Sun JX, Morley S, Spritz D, Ali S, Gay L, Erlich RL, Ross JS, Buxhaku J, Davies H, Faso V, Germain A, Glanville B, Miller VA, Stephens PJ, Janeway KA, Maris JM, Meshinchi S, Pugh TJ, Shern JF, Lipson D.

Cancer Res. 2017 Jan 15;77(2):509-519. doi: 10.1158/0008-5472.CAN-16-1106. Epub 2017 Jan 9.

46.

Reply to J.B. Aragon-Ching and D. Dalela et al.

Rusthoven CG, Jones BL, Kavanagh BD, Pugh TJ.

J Clin Oncol. 2017 Mar 10;35(8):916-917. doi: 10.1200/JCO.2016.70.9220. Epub 2016 Dec 12. No abstract available.

PMID:
27937090
47.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062. doi: 10.1172/jci.insight.87062.

48.

The genomic landscape of schwannoma.

Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y, Landon-Brace N, Tung T, Dowar M, Li T, Bruce JP, Burrell KE, Tonge PD, Alamsahebpour A, Krischek B, Agarwalla PK, Bi WL, Dunn IF, Beroukhim R, Fehlings MG, Bril V, Pagnotta SM, Iavarone A, Pugh TJ, Aldape KD, Zadeh G.

Nat Genet. 2016 Nov;48(11):1339-1348. doi: 10.1038/ng.3688. Epub 2016 Oct 10.

PMID:
27723760
49.

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.

Stockley TL, Oza AM, Berman HK, Leighl NB, Knox JJ, Shepherd FA, Chen EX, Krzyzanowska MK, Dhani N, Joshua AM, Tsao MS, Serra S, Clarke B, Roehrl MH, Zhang T, Sukhai MA, Califaretti N, Trinkaus M, Shaw P, van der Kwast T, Wang L, Virtanen C, Kim RH, Razak AR, Hansen AR, Yu C, Pugh TJ, Kamel-Reid S, Siu LL, Bedard PL.

Genome Med. 2016 Oct 25;8(1):109.

50.

Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer: Results From a Randomized Trial.

Hoffman KE, Skinner H, Pugh TJ, Voong KR, Levy LB, Choi S, Frank SJ, Lee AK, Mahmood U, McGuire SE, Schlembach PJ, Du W, Johnson J, Kudchadker RJ, Kuban DA.

Am J Clin Oncol. 2018 Jun;41(6):558-567. doi: 10.1097/COC.0000000000000325.

PMID:
27635624

Supplemental Content

Support Center